Viraday

Discount 10.00 usd
BRAND :  VIRADAY PRICE :  80$ STRENGTH : EFAVIRENZ 600 MG, EMTRICITABINE 200 MG ACTIVE :  VIRADAY-TENOFOVIR-300MG-EMTRICITABINE-200MG-EFAVIRENZ-600MG COMPANY NAME :  CIPLA... read more

80.00 usd
90.00
- +
Share

Drug profile of Viraday

Viraday tablets are containing active constituents which are having anti-retroviral activity drugs known as Tenofovir disoproxil fumarate, Efavirenz, Emtricitabine.

Viraday is a FDA approved product, which is active against HIV 1 infection condition.

Viraday containing components are;

Efavirenz: Non nucleoside reverse transcriptase inhibitor

Emtricitabine: Nucleoside reverse transcriptase inhibitors

Tenofovir DF: Nucleoside reverse transcriptase inhibitors.

All these drugs are involved in inhibiting reverse transcriptase enzyme which is essential for viral multiplication.

Viraday tablets are not considered as curable medicine, but it will diminish the amount of HIV in the body and prevent the further progression into AIDS.

 

Brand name: Viraday

Active substances: Efavirenz + Emtricitabine + Tenofovir disoproxil fumarate

Strength: 600mg + 200mg + 300mg respectively

Mfg: Cipla

Pack: 30 tablets in a container

Category: Anti-retroviral drug

 

Prescribing information of Viraday

The common prescribing information of Viraday tablets is used to treat HIV-1 infection by used alone or by combining with other anti-retroviral drugs.

A Viraday use is applicable for adults & pediatric patients about 12 years of age and older.

Mechanism of Viraday

Efavirenz:

Efavirenz exhibits anti-retroviral activity by inhibiting the reverse transcriptase enzyme which is essential viral RNA directed DNA polymerase enzyme.

The formation of active triphosphorylated form is necessary for the effect of efavirenz, variation occurs intracellularly.

Based on the cell type present in the body is required for phosphorylation.

The interfering of generation of DNA copies of viral RNA is occurred by inhibiting the enzyme RT.

This new DNA copies is required for new viral production.

This is concluded as inhibition of cell division.

Emtricitabine:

Emtricitabine is converted into active form known as Emtricitabine 5’ triphosphate which is essential for inhibition of viral proliferation. This metabolite fights with deoxycytidine 5’ triphosphate, is a natural substrate and get merged into viral DNA which leads to chain elimination.

Tenofovir DF:

This is similar to Emtricitabine, tenofovir is struggling with substrate called deoxyadenosine 5’ triphosphate and merged into DNA of virus which may concluded as prohibition of RT activity.

Finally viral multiplication gets affected.

NRT is an enzyme required for virion assembly, tenofovir DF causes inhibition of viral chain elongation and to produce immature destruction of DNA transcription, leads to obstruct the viral multiplication.

Tenofovir DF is a chain eliminator.

Absorption

Efavirenz plasma concentration time is 3 to 5 hours

Steady state of efavirenz is reached between 6 to 10days.

Emtricitabine plasma concentration time reaches within one hour.

Tenofovir bioavailability occurs by 25%

Maximum plasma concentration is 1.0 ± 0.4 hours.

Distribution

Volume of distribution of tenofovir is 1.3 ± 0.6L/kg.

Tenofovir has low plasma protein binding capacity with the range of 0.7 to 7.2%

Emtricitabine is highly bound to plasma protein by 80%.

Blood plasma ratio of Emtricitabine is 1.0

Human plasma protein binding capacity of efavirenz is by 99.5 to 99.7%.

Metabolism

The metabolism of efavirenz is involved by CYP3A & CYP2B6 isoenzymes.

The efavirenz metabolite is induced majorly by cytochrome isoenzymes to hydrolyzed metabolites.

The metabolism of tenofovir is not mediated by cytochrome enzymes.

The metabolism process of Emtricitabine is not so clear.

Excretion

Nearly 70% of Emtricitabine is occurred in urine, 13.7% in feces.

The terminal half life period of Emtricitabine is 10 hours.

The dose of tenofovir nearly 32% should be recovered in urine which is in unchanged form.

The terminal half life period of tenofovir is 17 hours.

The elimination of tenofovir is majorly occurs through glomerular filteration & tubular secretion.

The mean half life period of efavirenz is 52 to 76 hours

Elimination occurs via urine at 14 to 34%; feces at 16 to 61%.

When to take the Viraday

Viraday tablets should be taken on an empty stomach at bed time.

Dosage regimens of Viraday

The recommended dose of Viraday for both adults & pediatric patients with 12 years of age or older, one tablet should be taken as a single dose.

In renal impairment:

Viraday is a fixed dose combination tablet, if patient may require dosage adjustment should not recommended in moderate or severe conditions with the creatinine clearance below 50ml/min.

Rifampin concomitant use:

Patients with weigh of 50kg or more, Viraday should be combined with rifampin, by increasing dose of efavirenz 200mg/day.

Viraday caused side effects

The most common adverse effects;

Severe acute aggravation of hepatitis B

Lactic acidosis & hepatomegaly with steatosis

Nervous disorders

Newly commenced or worsening of renal impairment

Rash

Liver injury

Bone defects

Immune reconstitution syndrome

Redistribution of fat

Common side effects;

Diarrhea

Nausea

Vomiting

Fatigue

Infections & infestations

Sinusitis

Respiratory tract infections

Nasopharyngitis

Headache

Dizziness

Anxiety

Depression

Insomnia

Rash

Lab abnormality;

Increased levels of;

Cholesterol

Creatine kinase

Serum amylase

Alkaline phosphatase

AST, ALT

Blood glucose

Glycosuria

Neutropenia

Triglycerides

Post marketing reports:

Palpitations

Tinnitus

Vertigo

Gynecomastia

Abnormal vision

Constipation

Malabsorption

Asthenia

Hepatobiliary disorders

Allergy

Pancreatitis

Drug- drug interaction

The substrate of CYP3A or CYP2B6 combined with Viraday, causes decreasing plasma concentration of these substrates.

Viraday with CYP3A inducers causes increasing clearance of efavirenz leads to decreasing the plasma concentrations.

Co administration of Viraday with drugs which reduce the renal functions may leads to increase the plasma concentration of Emtricitabine & tenofovir DF leads to increase the adverse effects.

Viraday tablets combined with atazanavir & other protease inhibitors, causes decreasing the effect of concentration of atazanavir and increasing the tenofovir concentration.

Viraday with Didanosine causes increasing effect of concentration of Didanosine

Viraday with other NNRTI leads to cause increasing or decreasing the effect of concentration of efavirenz.

Viraday with anti-coagulant, anti-convulsants, anti-depressants, or anti-fungals leads to cause decreasing the effect of concentration of these following drugs.

Viraday combined with any anti-infective, anti-mycobacterials, anti-malarial or calcium channel blocker causes decreasing the effect of concentration of these drugs.

Viraday with lipid lowering drugs, hormonal contraceptives or immuno suppressants, causes decreasing effect of concentration of these drugs.

Food drug interaction

Viraday tablets are administered on an empty stomach, at bedtime because of decreasing neurological problems.

Possible contraindications

Anaphylactic reactions may produce due to patients may contraindicate to the component present in the Viraday tablets.

Viraday is contraindicated to some drugs like;

Voriconazole

The co administration of Viraday with voriconazole, efavirenz one of the active component present in Viraday causes depletion of plasma concentration of voriconazole which may leads to loss of therapeutic effects.

Safety measures

The potency of Viraday has not been evaluated in patient with HIV-1 HBV co infections.

Hepatic function test should be undergone periodically for preventing aggravation of hepatitis infection in patients who are discontinuing the therapy.

Safety precautions should be taken in the patients who are suspected with;

Patients co infected with HIV-1 HBV

Drug interactions

Lactic acidosis or hepatomegaly with steatosis: Stop the treatment

Co administration of some drugs: Some concomitant use of drugs should be cause adverse effects.

QT prolongation: monitor ECG periodically and patients may treat with alternative medications.

Psychiatric symptoms: risk factors should be frequently and provided with supportive measures

Nervous symptoms: To reduce the symptoms, Viraday should be taken at bed time

Renal impairment: In severe condition, discontinue the treatment.

Reproductive risk: Viraday is contraindicated to pregnancy condition. Avoid becoming pregnant

Rash: Alternative treatment should be provided

Liver toxicity: Liver function test should be taken periodically

Bone defects: Vitamin D supplements should be given to the patients, monitor the bone mineral density.

Convulsions: Provide with anti-convulsants medication and monitor the risk of seizures.

Immune reconstitution syndrome: Discontinue the therapy

Redistribution of fat: Discontinue the treatment. The major risk of fat redistribution is obesity

Pregnancy and lactation

Pregnancy category D

Viraday should not be used in pregnancy and lactating period.

Storage and handling

Viraday tablet container should be stored at 25oC (77oF)

Protect the container from moisture, heat & light

Missed dose

Missed dose of Viraday should be avoided.

In case of missed dose of Viraday, must be consult with medical practitioner and follow the instructions.

Regular dosing schedule of Viraday tablet should be maintained.

Over dosage

The over dosage of Viraday tablets are occurred due to missed dose.

The over dosage of efavirenz is caused nervous system symptoms.

Nearly 3 hours of dialysis process, eliminates 30% of Emtricitabine dose from the body within 1.5 hours of dosing time.

Tenofovir is easily removed with the range of 54% by undergoing dialysis.

On 4 hours dialysis process, nearly 10% of dose should be removed from the body.

 

    No comments yet
Write a comment
Your name
Your name
Captcha

Sale of day

Choice of buyers. Only popular options!Choice of buyers.
Only popular options!

view all
Abbott
Biocon
Cipla
Dr. Reddy’s
Eisai
Emcure
Hetero
Intas
MSD
Mylan
Natco
Novartis
Strides
Zydus
  • Children born with HIV
    Children born with HIV
    Children born with HIV accessing treatment, have no significant difference in their movement skills, social interaction, language skills or practical reasoning at age five compared to HIV-negative children, according to new research....